Welcome to our dedicated page for Longeveron SEC filings (Ticker: LGVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Longeveron Inc. filings document a clinical-stage biotechnology issuer developing laromestrocel, an investigational allogeneic cellular therapy, and its related regulatory, financing, governance, and listing disclosures. Form 8-K reports cover FDA communications, clinical-development updates, material agreements, executive and board compensation matters, shareholder meeting actions, and Nasdaq continued-listing notices.
Registration statements and event reports also identify LGVN’s Class A common stock, Nasdaq Capital Market listing, emerging growth company status, and financing-related securities disclosures. The filing record ties the company’s public-company reporting to clinical and regulatory development of laromestrocel, stockholder voting matters, and capital resources used to fund biotechnology operations.
Longeveron Inc. (LGVN) reports that it has regained compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq notified the company on September 11, 2026 that the Class A common stock closed at or above $1.00 for 10 consecutive business days, from August 27, 2026 through September 10, 2026, satisfying Nasdaq Listing Rule 5550(a)(2). This follows an initial non-compliance notice in September 2025 and two 180-day grace periods extending the deadline to September 21, 2026; Nasdaq now considers the matter closed.
Longeveron Inc. (LGVN) has a new large shareholder disclosure, as Logos Global Management LP and affiliated entities reported beneficial ownership of 192,308 shares of Longeveron Class A common stock on a Schedule 13G. This represents 6.3% of the Class A shares outstanding after Longeveron’s 1-for-10 reverse stock split on August 26, 2026.
The shares are held by Logos Opportunities Fund V LP for the benefit of its investors, with Logos Global acting as investment adviser and related general partner entities and individuals Arsani William and Graham Walmsley listed as reporting persons. All reporting persons have shared voting and dispositive power over the 192,308 shares and no sole power. They state the position is not held for the purpose of changing or influencing control of Longeveron and that each disclaims beneficial ownership beyond their pecuniary interest.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (LGVN) reported an initial ownership filing for Jhaveri Nirav S., who serves as Chief Financial Officer. The filing shows a holding line for Class A Common Stock with 0 shares beneficially owned, as confirmed by a footnote stating that no securities are beneficially owned.
Longeveron Inc. (LGVN) is implementing a 1-for-10 reverse stock split of its Class A and Class B common stock. Stockholders approved a reverse-split range on July 1, 2026, the board set the final 1:10 ratio on July 31, 2026, and a certificate of amendment was filed in Delaware on August 20, 2026. The split becomes effective at 11:59 p.m. Eastern Time on August 26, 2026, and the Class A shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market on August 27, 2026 under the same ticker “LGVN” and a new CUSIP 54303L 302. Every ten existing shares will be combined into one share, with fractional shares rounded up at the DTC participant level and no cash paid. The split will reduce outstanding Class A shares from about 30.4 million to about 3.0 million and Class B shares from about 1.45 million to about 0.15 million, while authorized share counts and par value remain unchanged. Longeveron states the reverse split is intended to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (symbol LGVN) reported that a director, identified as the reporting person, received an equity compensation award in the form of Class A Common Stock. On 2026-08-19, the reporting person acquired 36,000 shares through an award of time-based vesting Restricted Stock Units (RSUs) at a stated price of $0.00 per share.
After this grant, the reporting person directly holds 69,000 shares of Class A Common Stock, which the disclosure states includes RSUs subject to future vesting. The transaction is characterized as a grant, award, or other acquisition and was not reported as made pursuant to a Rule 10b5-1 trading plan.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.
Longeveron Inc. (symbol: LGVN) is the issuer of record for a Form 4 filing submitted to the SEC.